Highlights:
This medical company sells a best-selling imaging agent for the identification of cancer cells.
Profits have risen tenfold in just two years. Yet the stock trades at only 11x earnings.
Investors are focussed on fears of competition. But they may be overlooking the company’s first-mover advantage and unique strengths.
Keep reading with a 7-day free trial
Subscribe to Overlooked Alpha to keep reading this post and get 7 days of free access to the full post archives.